Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1

Status

Active not recruiting 2Terminated 1Completed 1

Sponsor Class

OTHER 2NIH 1INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4

Conditions

Breast Neoplasms 189Neoplasm Metastasis 24Neoplasms 23Ovarian Neoplasms 12Sarcoma 10Pancreatic Neoplasms 9Squamous Cell Carcinoma of Head and Neck 8Melanoma 7Endometrial Neoplasms 7Colorectal Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Prostatic Neoplasms 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Multiple Myeloma 6Lymphoma, Non-Hodgkin 6Head and Neck Neoplasms 6Carcinoma, Renal Cell 6Breast Diseases 6Recurrence 5Medulloblastoma 5Lung Neoplasms 5Leukemia, Myeloid, Acute 5Triple Negative Breast Neoplasms 4Sarcoma, Ewing 4Neoplasms by Site 4Lymphoma, Mantle-Cell 4Liposarcoma 4Glioma 4Glioblastoma 4Colonic Neoplasms 4

Interventions

Rituximab 226Cyclophosphamide 202fludarabine phosphate 108Peripheral Blood Stem Cell Transplantation 103Filgrastim 87Etoposide 76Cytarabine 70ibrutinib 68Mycophenolic Acid 67Bortezomib 66Whole-Body Irradiation 63Cyclosporine 63Melphalan 59Lenalidomide 59Bendamustine Hydrochloride 58Vincristine 53Radiotherapy 53fludarabine 52Tacrolimus 50Doxorubicin 48Busulfan 48Methotrexate 47Antilymphocyte Serum 42Prednisone 41Carmustine 40Dexamethasone 38Granulocyte Colony-Stimulating Factor 33venetoclax 31acalabrutinib 31zanubrutinib 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Lymphoma, Mantle-Cell × palbociclib × Clear all
NCT02159755 2026-05-27

Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma

National Cancer Institute (NCI)

Phase 1 Active not recruiting
28 enrolled
Lymphoid

Lymphoma, Mantle-Cell

NCT03478514 2026-04-09

Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma

Alliance Foundation Trials, LLC.

Phase 2 Active not recruiting
39 enrolled
Lymphoid

Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT01111188 2019-06-27

Trial of PD 0332991 Plus Bortezomib in Patients With Relapsed Mantle Cell Lymphoma

Weill Medical College of Cornell University

Phase 1 Terminated
20 enrolled
Lymphoid

Lymphoma, Mantle-Cell

NCT00420056 2015-10-28

An Investigational Study Drug, Palbociclib (PD-0332991), Is Being Studied In Patients With Mantle Cell Lymphoma. Patients Must Have Received Prior Treatment(s) For Mantle Cell Lymphoma.

Pfizer

Phase 1 Completed
17 enrolled 22 charts
Lymphoid

Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡